info@clinicalsurgeryjournal.com

Shigeo Masuda

Shigeo Masuda

Shigeo Masuda

MD, PhD Osaka University Graduate School of Medicine, Department of Cardiovascular Medicine Japan

BIOGRAPHY 10 PUBLICATIONS 45 ACCOMPLISHMENTS 5

We cordially invite you to join our board.

Your valuable suggestions improve our journal quality. We welcome you to be part of our board members.

Join Board

Dr. Shigeo Masuda received his MD from the University of Tokyo in 1996, and Ph.D. in Hematology/Oncology from the Graduate School of Medicine, University of Tokyo, Japan.

He was an Assistant Professor and an Associate Professor at Jichi Medical University, Japan, from 2007 to 2012, and joined RIKEN CDB in 2011. He studied at the Belmonte Lab in the Salk Institute from 2012 to 2014. Currently, he is an Associate Professor of Cardiovascular Surgery at Osaka University, Japan. His interest in regenerative medicine using iPS-derived cells, including molecular targeted therapy for iPS-derived undifferentiated cells to improve safety.

Field of Expertise

  • Molecular Targeted Therapy.
  • Induced Pluripotent Stem Cell.
  • Regenerative Medicine.

Recent Publications

  • Iseoka H, Miyagawa S, Fukushima S, Saito A, Masuda S, Yajima S, Ito E, Sougawa N, Takeda M, Harada A, Lee JK, Sawa Y. Pivotal role of non-cardiomyocytes in electromechanical and therapeutic potential of induced pluripotent stem cell-derived engineered cardiac tissue. Tissue Eng Part A. 24(3-4): 287-300, 2018.
  • Masuda S. Atherosclerosis: Caused by Mutated Old Blood Cells. [Editorial] Ann Cardiol Cardiovasc Med. 1(1): 1002, 2017.
  • Masuda S, Miyagawa S, Sawa Y. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med. 376(18): e38, 2017.
  • Masuda S, Miyagawa S, Nakamura T, Khurram MA, Sawa Y. Brentuximab vedotin for CD30-positive tumours. Lancet Oncol. 17(9): e371, 2016.
  • Masuda S, Miyagawa S, Fukushima S, Nakamura T, Khurram MA, Ishikawa T, Saito A, Sawa Y. Expandable progenitors from induced pluripotent stem cells. Nat Rev Cardiol. 13(10): 574, 2016.
  • Miyagawa S, Fukushima S, Imanishi Y, Kawamura T, Mochizuki-Oda N, Masuda S, Sawa Y. Building a new treatment for heart failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart. Curr Gene Ther. 16(1): 5-13, 2016.
  • Kawamura A, Miyagawa S, Fukushima S, Kawamura T, Kashiyama N, Ito E, Watabe T, Masuda S, Toda K, Hatazawa J, Morii E, Sawa Y. Teratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Rejection in Mice. Sci Rep. 6: 19464, 2016.
  • Masuda S, Miyagawa S, Fukushima S, Sougawa N, Okimoto K, Tada C, Saito A, Sawa Y. Eliminating residual iPS cells for safety in clinical application. Protein Cell. 6(7): 469-471, 2015.
  • Masuda S, Miyagawa S, Fukushima S, Sougawa N, Okimoto K, Saito A, Sawa Y. CD30-targeting immunoconjugates and bystander effects. Nat Rev Clin Oncol. 12(4): 245, 2015.
  • Masuda S, Miyagawa S, Fukushima S, Kawamura T, Kashiyama N, Saito A, Sawa Y. Regulating ES or Induced Pluripotent Stem Cells by Innate Lymphoid Cells. Transplantation. 98(5): e38-e39, 2014.
  • Liu GH, Suzuki K, Li M, Qu J, Montserrat N, Tarantino C, Gu Y, Yi F, Xu X, Zhang W, Ruiz S, Plongthongkum N, Zhang K, Masuda S, Nivet E, Tsunekawa Y, Soligalla RD, Goebl A, Aizawa E, Kim NY, Kim J, Dubova I, Li Y, Ren R, Benner C, del Sol A, Bueren J, Trujillo JP, Surralles J, Cappelli E, Dufour C, Esteban CR, Izpisua Belmonte JC. Modelling Fanconi Anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs. Nat Commun. 5: 4330, 2014.
  • Masuda S, Miyagawa S, Fukushima S, Sougawa N, Ito E, Takeda M, Saito A, Sawa Y. Emerging innovation towards safety in the clinical application of ESCs and iPSCs. Nat Rev Cardiol. 11(9): 553-554, 2014.
  • Masuda S, Izpisua Belmonte JC. A recipe for targeted therapy in prostate cancer. Nat Rev Urol. 11(7): 419-420, 2014.
  • Masuda S, Izpisua Belmonte JC. Re: Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer. J Natl Cancer Inst. 106(3): djt457, 2014.
  • Masuda S, Wu J, Hishida T, Pandian GN, Sugiyama H, Izpisua Belmonte JC. Chemically induced pluripotent stem cells (CiPSCs): a transgene-free approach. J Mol Cell Biol. 5(5): 354-355, 2013.
  • Masuda S, Suzuki K, Izpisua Belmonte JC. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med. 369(12): 1170-1172, 2013.
  • Li M, Kim NY, Masuda S, Izpisua Belmonte JC. Regulation of somatic stem cell function by DNA methylation and genome imprinting. Cell Tissue Transplant Ther. 5: 19–23, 2013.
  • Masuda S. A putative link among the triad: inflammation, reprogramming, and cancer. [Editorial] J Tumor. 1(2): 5-6, 2013.
  • Masuda S, Izpisua Belmonte JC. The microenvironment and resistance to personalized cancer therapy. Nat Rev Clin Oncol. 10(2): 79, 2013.
  • Masuda S, Izpisua Belmonte JC. At the crossroads of targeted treatment and resistance in melanoma. Lancet Oncol. 14(4): e136-e137, 2013.
  • Masuda S, Li M, Izpisua Belmonte JC. Niche-less maintenance of HSCs by 2i. Cell Res. 23(4): 458-459, 2013.
  • Masuda S, Izpisua Belmonte JC. Cotransplantation of MSCs and HSCs. Transplantation. 95(10): e62-e63, 2013.
  • Masuda S, Li M, Izpisua Belmonte JC. In vitro generation of platelets through direct conversion: first report in My Knowledge (iMK). Cell Res. 23(2): 176-178, 2013.
  • Masuda S, Montserrat N, Okamura D, Suzuki K, Izpisua Belmonte JC. Cardiosphere-derived cells for heart regeneration. Lancet. 379(9835): 2425-2426, 2012.
  • Masuda S, Izpisua Belmonte JC. Trametinib for patients with advanced melanoma. Lancet Oncol. 13(10): e409, 2012.
  • Masuda S, Yokoo T, Sugimoto N, Doi M, Fujishiro S, Takeuchi K, Kobayashi E, Hanazono Y. A simplified in vitro teratoma assay for pluripotent stem cells injected into rodent fetal organs. Cell Med. 3(1): 103-112, 2012.
  • Masuda S. Cardiac stem cells in patients with ischaemic cardiomyopathy. Lancet. 379(9819): 891-892, 2012.
  • Abe T, Masuda S, Tanaka Y, Nitta S, Kitano Y, Hayashi S, Hanazono Y, Nagao Y. Maternal Administration of Busulfan Before in Utero Transplantation of Human Hematopoietic Stem Cells Enhances Engraftments in Sheep. Exp Hematol. 40(6): 436-444, 2012.
  • Masuda S. Regulatory T cells in Graft-versus-Host Disease. N Engl J Med. 366(10): 962-963, 2012.
  • Masuda S. Re: Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response. J Natl Cancer Inst. 104(5): 421-422, 2012.
  • Masuda S. Risk of teratoma formation after transplantation of induced pluripotent stem cells. Chest. 141(4): 1120-1121, 2012.
  • Masuda S. Dysfunctional transforming growth factor-ß signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer. 118(7): 1957-1958, 2012.
  • Masuda S, Hayashi S, Ageyama N, Shibata H, Abe T, Nagao Y, Hanazono Y. Migration of cells from the yolk sac to hematopoietic tissues after in utero transplantation of early and mid gestation canine fetuses. Transplantation. 92(2): e5-6, 2011.
  • Masuda S. Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 365(24): 2336-2338, 2011.
  • Masuda S. Point mutations in myelodysplastic syndromes. N Engl J Med. 365(12): 1154-1155, 2011.
  • Masuda S. Evidence for human lung stem cells. N Engl J Med. 365(5): 464-465, 2011.
  • Masuda S. More on NK-cell and B-cell deficiency with a thymic mass. N Engl J Med. 364(20): 1979-1981, 2011.
  • Masuda S, Hanazono Y. Induced pluripotent stem cells in long-QT syndrome. N Engl J Med. 364(2): 181-182, 2011.
  • Abe T, Masuda S, Ban H, Hayashi S, Ueda Y, Inoue M, Hasegawa M, Nagao Y, Hanazono Y. Ex vivo expansion of human HSCs with Sendai virus vector expressing HoxB4 assessed by sheep in utero transplantation. Exp Hematol. 39(1):47-54, 2011.
  • Masuda S. Leukemic stem cell gene expression signature and clinical outcomes in acute myeloid leukemia. JAMA. 305(11): 1094-1095, 2011.
  • Masuda S. DNMT3A mutations in acute myeloid leukemia: impact on low risk patients with CEBPA mutations. J Clin Oncol. 29(34): 4592-4593, 2011.
  • Masuda S. Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol. 22(11): 2533-2534, 2011.
  • Tanaka Y, Masuda S, Abe T, Hayashi S, Kitano Y, Nagao Y, Hanazono Y. Intravascular route is not superior to an intraperitoneal route for in utero transplantation of human hematopoietic stem cells and engraftment in sheep. Transplantation. 90(4): 462-463, 2010.
  • Masuda S, Ageyama N, Shibata H, Obara Y, Ikeda T, Takeuchi K, Ueda Y, Ozawa K, Hanazono Y. Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. Exp Hematol. 37(10): 1250-1257, 2009.
  • Masuda S, Kumano K, Suzuki T, Tomita T, Iwatsubo T, Natsugari H, Tojo A, Shibutani M, Mitsumori K, Hanazono Y, Ogawa S, Kurokawa M, Chiba S. Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Sci. 100(12): 2444-2450, 2009.

Awards

  • 2011: Japan Society of Gene Therapy Award (the Japan Society of Gene Therapy).
  • 2010: Young Investigator’s Award (the Japanese Society for Regenerative Medicine).
  • 2007: Incitement Award (the Japanese Cancer Association).
  • 2005: Incitement Award (the Japanese Society of Hematology).
  • 2005: Young Investigator’s Award (the Japan Prize Foundation).

Patent

  • International Application No. PCT/ JP2015/081408. Filed on November 6, 2015.
  • Applicant: Osaka University.

Are you interested in submitting your research paper?

Thank you for choosing us. We recommend you to go through our guidelines before submitting the paper.

Submit Manuscript
Logo

Clinical Surgery Journal is the state-of-the-art platform to showcase medical journals across scientific community and a one-stop solution for publishing the manuscripts of varied medical specialities.

Main Links

Useful Links

Our Contacts

CLINICAL SURGERY JOURNAL,
C/O Infact Publications LLC,
16192 Coastal Highway,
Lewes, Delaware 19958
USA

info@clinicalsurgeryjournal.com
https://clinicalsurgeryjournal.com